Semaglutide (Ozempic/Wegovy) and Mounjaro (tirzepatide) are frequently confused — but they are different molecules with different mechanisms. Here's the complete comparison.
Semaglutide and Ozempic/Wegovy are the same molecule. Mounjaro and Zepbound contain tirzepatide — a different molecule. Semaglutide is a GLP-1 receptor agonist. Tirzepatide (Mounjaro) is a dual GLP-1/GIP receptor agonist. They are related but distinct compounds.
| Feature | Semaglutide (Ozempic/Wegovy) | Mounjaro (Tirzepatide) |
|---|---|---|
| Active molecule | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist |
| Brand names (Rx) | Ozempic (diabetes), Wegovy (obesity) | Mounjaro (diabetes), Zepbound (obesity) |
| Research form | Semaglutide peptide | Tirzepatide peptide |
| Weight loss (Phase 3) | ~15% body weight (SUSTAIN-6) | ~22.5% body weight (SURMOUNT-1) |
| GLP-1 activity | Full GLP-1 agonist | GLP-1 + GIP dual agonist |
| GIP activity | None | Full GIP agonist |
| Nausea profile | Moderate (30–44% incidence) | Similar to semaglutide at equivalent doses |
| Dosing frequency | Once weekly | Once weekly |
| FDA approval | 2021 (Wegovy), 2017 (Ozempic) | 2023 (Mounjaro), 2023 (Zepbound) |
| Research availability | Widely available | Widely available |
The key mechanistic difference between semaglutide and tirzepatide is GIP receptor agonism. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances insulin secretion and has direct effects on adipose tissue. Tirzepatide's dual GLP-1/GIP mechanism is believed to explain its superior weight loss outcomes compared to semaglutide in clinical trials. GIP receptors are expressed in adipocytes, and GIP agonism may directly reduce fat cell size and number. Semaglutide acts only on GLP-1 receptors, producing appetite suppression, delayed gastric emptying, and insulin sensitization — but without the additional GIP-mediated adipose effects.
No. Semaglutide (Ozempic/Wegovy) and Mounjaro (tirzepatide) are different molecules. Semaglutide is a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which is a dual GLP-1/GIP receptor agonist. They work through related but distinct mechanisms.
Clinical trial data shows tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy) — approximately 22.5% vs 15% body weight in Phase 3 trials. However, individual responses vary significantly, and direct head-to-head trials are limited.
Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The addition of GIP agonism is believed to enhance tirzepatide's metabolic effects, including greater insulin sensitization and potentially greater weight loss. Both are once-weekly injectable peptides.
Switching between GLP-1 compounds is a clinical decision that requires medical supervision. In research contexts, both semaglutide and tirzepatide are studied as separate compounds with distinct protocols. The titration schedules differ between the two compounds.
Mounjaro (tirzepatide) has shown greater average weight loss in clinical trials compared to Ozempic (semaglutide). However, 'stronger' depends on the endpoint — for cardiovascular outcomes, semaglutide has more published long-term data. For weight loss specifically, tirzepatide has demonstrated superior results in head-to-head analyses.
Both are well-studied research compounds. Semaglutide has a longer published research history and more cardiovascular outcome data. Tirzepatide has stronger weight loss data and the additional GIP mechanism provides more research angles. The choice depends on the specific research application.
Purgo Labs carries both semaglutide and tirzepatide with third-party COAs. Use code HEALTH for 15% off.
Shop at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.